20.500.12556/RUL-154097 Anti-vimentin nanobody decreases glioblastoma cell invasion in vitro and in vivo Purpose: Glioblastoma (GBM) is the most common primary brain tumour and one of the deadliest cancers. In addition to late diagnosis and inadequate treatment, the extremely low survival rate is also due to the lack of appropriate therapeutic biomarkers and corresponding therapeutic agents. One of the potential therapeutic biomarkers is the intermediate filament vimentin, which is associated with epithelial-mesenchymal transition (EMT). The purpose of this study was to analyse the effect of the anti-vimentin nanobody Nb79 on cell invasion in vitro and in vivo. To further our understanding of the mechanism of action, we investigated the association between Nb79 and EMT in GBM and GBM stem cells by analysing the expression levels of key EMT-related proteins. Methods: The expression of vimentin in glioma tissues and cells was determined by RT-qPCR. An invasion assay was performed on differentiated glioblastoma cell line U-87 MG and stem cell line NCH421k in vitro as well as in vivo in zebrafish embryos. The effect of Nb79 on expression of EMT biomarkers beta-catenin, vimentin, ZEB-1 and ZO1 was determined by Western blot and immunocytochemistry. Results: Our study shows that vimentin is upregulated in glioblastoma tissue compared to lower grade glioma and non-tumour brain tissue. We demonstrated that treatment with Nb79 reduced glioblastoma cell invasion by up to 64% in vitro and up to 21% in vivo. In addition, we found that the tight junction protein ZO-1 had higher expression on the cell membrane, when treated with inhibitory anti-vimentin Nb79 compared to control. Conclusion: In conclusion, our results suggest that anti-vimentin nanobody Nb79 is a promising tool to target glioblastoma cell invasion. glioblastoma vimentin nanobody invasion EMT glioblastom vimentin nanotelo true false true Angleški jezik Slovenski jezik Članek v reviji 2024-01-25 08:35:11 2024-01-25 08:35:15 2024-01-27 03:16:16 0000-00-00 00:00:00 2023 0 0 14 str. iss. 3, art. 573 Vol. 15 2023 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-006 2072-6694 10.3390/cancers15030573 138228995 cancers-15-00573-v2.pdf cancers-15-00573-v2.pdf 1 20A08AEB81A7FB4472C0B7E6E26554AB f3c8c7b6f82ed226014225785a833ff0a7179a53edb14f594405784abe48efa8 ce6d5daf-bb54-11ee-9ead-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=180268 https://www.mdpi.com/2072-6694/15/3/573 1 49998751-bb54-11ee-9ead-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=180267 Medicinska fakulteta Biotehniška fakulteta Fakulteta za kemijo in kemijsko tehnologijo 0 0 0